

REMARKS

FORMAL MATTERS:

Claims 1-27 were examined and rejected.

By this Amendment, claims 1-18 and 21-27 have been canceled without prejudice, claim 19 has been amended to incorporate the limitation of original claim 22.

Claims 19 and 20 are pending after entry of the amendments set forth herein.

REJECTIONS UNDER §103

Claims 1-27 were rejected under 35 U.S.C. §103(a) as being unpatentable over Elander (U.S. Patent No. 4,500,750) in view of Obashi (U.S. Patent No. 5,761,309).

As claims 1-18 and 21-27 have been canceled, the rejection with respect to these claims has been made moot.

With respect to claim 19, the Examiner states that Elander discloses a method for authentication of a user involving the use of cyclic redundancy values. This is simply not the case. Elander is directed to encryption and not cyclic redundancy values which having nothing to do with encryption. Obashi fails to make up for the deficiencies of Elander. Accordingly, claim 19 and claim 20 which is dependent thereon, are patentable in view of Elander and Obashi, either alone or in combination.


CONCLUSION

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number LIFE-061.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 04/05/05

By: 
Carol M. LaSalle
Registration No. 39,740

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\LIFE\061\resp to oa 11-17-2004.doc